# Bronchogen: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on Bronchogen — the lung/bronchial 'bioregulator' tetrapeptide (ADEL/AEDL) from the Khavinson short-peptide program. Promising preclinical biology, zero human efficacy or safety trials, and an unapproved 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Bronchogen is a four-residue lung 'bioregulator' tetrapeptide with an intriguing *rat-COPD and cell-culture* story, but **no human randomized trials, no cohorts, and no registered trials exist** — so its highest evidence grade is **C (preclinical only)**. It is not FDA-approved, is sold as a research chemical not for human use, and as an unapproved substance is plausibly prohibited in sport under WADA category S0.[1](https://peptidevox.com/#r1)[9](https://peptidevox.com/#r9)

Bronchogen is a synthetic tetrapeptide from Vladimir Khavinson's St. Petersburg 'bioregulator' program, proposed as a lung- and bronchial-tissue-specific gene-expression modulator.[1](https://peptidevox.com/#r1) It is promoted in longevity and respiratory-recovery circles as an organ-specific peptide for the aging lung; its proof in humans is nonexistent. This monograph separates the mechanistic biology from the clinical claims.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Bronchogen is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is plausibly prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is Bronchogen and how is it proposed to work?

Bronchogen is an ultrashort, four-residue peptide said to be modeled on peptide fragments isolated from bronchial mucosa, with molecular formula C18H30N4O9 and a molecular weight of roughly 446.5.[1](https://peptidevox.com/#r1) Its sequence is reported inconsistently across the literature: most primary papers and the original DNA work specify **Ala-Asp-Glu-Leu (ADEL)**, while commercial vendors and some later methylation papers list **Ala-Glu-Asp-Leu (AEDL)** — a transposed aspartate/glutamate order denoting the same product.[3](https://peptidevox.com/#r3)[4](https://peptidevox.com/#r4) When even the originating literature disagrees on residue order, precise specificity claims deserve scrutiny.

The proposed mechanism is unusual and not established in mainstream molecular biology. Unlike growth-factor or hormone-mimetic peptides, the Khavinson model holds that these di- to tetrapeptides enter cells and the nucleus and act as **epigenetic regulators by binding DNA and histones directly**, with no classical membrane receptor.[1](https://peptidevox.com/#r1) Spectrophotometry, viscometry and circular dichroism indicated ADEL binds double-stranded DNA in the major groove at the N7 of guanine.[1](https://peptidevox.com/#r1) An earlier biophysical study reported the peptide alters DNA melting and thermostability.[3](https://peptidevox.com/#r3) In a tobacco model, 10⁻⁷ M AEDL reduced condensed-chromatin domains from roughly 45% to 25% of nuclear area, interpreted as decondensation toward transcriptionally active euchromatin via histone interaction.[4](https://peptidevox.com/#r4) A follow-up reported preferential binding at the CTG methylation site, proposed to gate DNA-methyltransferase access.[5](https://peptidevox.com/#r5) No formal human pharmacokinetic dataset — Cmax, half-life, clearance, bioavailability — has ever been published; oral dosing rests on a class-level claim that 2-to-4-residue peptides are partly absorbed via the intestinal transporters PEPT1 and PEPT2.[6](https://peptidevox.com/#r6)

## What is the evidence by indication?

There are no human randomized controlled trials, no registered [ClinicalTrials.gov](https://clinicaltrials.gov/) entries with results, and no indexed cohort or observational efficacy studies for Bronchogen. All efficacy evidence is preclinical — rat in vivo plus human and plant cell systems — and nearly all of it originates from one Russian research lineage without independent Western replication. Every indication below is graded accordingly.

  Bronchogen evidence by indication

    IndicationBest evidenceGrade

    COPD / chronic bronchitis (bronchial-epithelial repair & anti-remodeling)Rat NO2-induced COPD model: reversed remodeling, restored mucosal immunityC (preclinical, in vivo)
    Bronchial-epithelial differentiation & lung 'geroprotection'Human embryonic bronchial cell cultures: differentiation-gene up-regulationC (preclinical, in vitro)
    Surfactant support / alveolar stabilitySFTPA1 up-regulation in culture; indirect animal reportsC-to-D
    Asthma, pulmonary fibrosis, COVID-19 lung protection, anti-agingMechanistic / marketing extrapolation onlyD (unproven)

The strongest single study modeled COPD in rats by 60 days of intermittent NO₂ exposure; one month of Bronchogen therapy reversed hallmark remodeling — goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema — and restored ciliated cells, increased secretory IgA, and normalized bronchoalveolar lavage cell composition and pro-inflammatory cytokines.[2](https://peptidevox.com/#r2) This is a rodent histopathology study with no functional pulmonary outcomes, no human data, and a single lab — animal-only, Grade C, not to be extrapolated to human COPD efficacy. In human embryonic bronchial-epithelial cultures across early and late passages, ADEL modulated proliferation and apoptosis proteins (Ki67, Mcl-1, p53) — with the strongest pro-proliferative effect in late-passage 'old' cultures — and up-regulated differentiation genes NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2 plus MUC and SFTPA1.[1](https://peptidevox.com/#r1) The 'geroprotective lung' framing is the authors' interpretation of cell-culture senescence, not demonstrated benefit in elderly humans.

Proven vs hyped
Proven in humans: nothing. Hyped: vendor claims for asthma, pulmonary fibrosis, COVID-19 lung protection, 'oxygen exchange,' surfactant production and anti-aging — all Grade D extrapolation with no controlled efficacy evidence.[7](https://peptidevox.com/#r7) The honest read is promising preclinical biology with zero human validation.

## What doses appear in the literature?

Reported strictly as information, not a protocol. No regimen below has been validated in a controlled human trial or sanctioned by any drug regulator, and there is no established human dose-response, no maximum tolerated dose, and no titration data.[6](https://peptidevox.com/#r6) The Khavinson bioregulator convention is short pulsed courses of roughly 10 to 20 days, repeated one to two times per year, rather than continuous daily dosing.[6](https://peptidevox.com/#r6) Oral 'Cytomax/Cytogen' capsule forms are taken once daily on an empty stomach during a course, with oral doses set higher than injectable to compensate for limited absorption; a frequently quoted vendor figure is about 200 micrograms per day orally — vendor-sourced, not trial-validated.[6](https://peptidevox.com/#r6) An injectable research-chemical form is sold as a lyophilized powder (commonly 20 mg vials) labeled 'research use only,' reconstituted with bacteriostatic or sterile water; no sterility, potency, or endotoxin assurance applies to research-grade material.[10](https://peptidevox.com/#r10) Russian respiratory practice describes pairing Bronchogen with Chonluten (Glu-Asp-Gly) for bronchopulmonary support.[6](https://peptidevox.com/#r6)

## How safe is Bronchogen?

Human safety data are essentially none: no controlled human trials means no adverse-event tables, no laboratory-monitoring data, and no long-term safety profile exist, so claims of an 'excellent safety profile' are extrapolated from low-dose animal and cell work and class reputation, not demonstrated in humans.[1](https://peptidevox.com/#r1) There is a theoretical mechanistic concern: any agent that drives epithelial proliferation (Ki67, Mcl-1) and alters DNA-methylation gating warrants caution in the setting of active or prior malignancy until properly studied — a first-principles caution, not an observed harm.[5](https://peptidevox.com/#r5) Drug interactions are unstudied. The dominant real-world hazard is product quality: material sold as a research chemical, frequently injectable, carries no FDA assurance of identity, purity, sterility, or endotoxin limits, and the FDA has issued warning letters to facilities marketing such peptides for human use.[10](https://peptidevox.com/#r10) Pregnancy, lactation, children, and active malignancy are precautionary contraindications.

## What is the FDA and WADA status in 2026?

Bronchogen has no FDA approval — no NDA or BLA, no recognized therapeutic indication, and it is not a dietary-supplement-eligible ingredient for disease claims. It is marketed under the 'research use only, not for human consumption' framing and sits outside both the 503A compounding-pharmacy and 503B outsourcing-facility pathways; the broader 2024-2026 peptide-compounding tightening — bulk-substance review and warning letters — reinforces that such research peptides are not lawful for human compounding or administration.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11) It is not a DEA controlled substance. In Russia and Eastern Europe, Khavinson bioregulators are distributed as registered food supplements or parapharmaceuticals, which is not equivalent to FDA or EMA drug approval.[6](https://peptidevox.com/#r6)

For athletes the relevant fact is regulatory rather than evidentiary. Bronchogen is not explicitly named on the 2026 WADA Prohibited List, which came into force on 1 January 2026.[8](https://peptidevox.com/#r8) However, category S0 (Non-Approved Substances) prohibits, at all times, any pharmacological substance not approved by any governmental health authority for human therapeutic use.[9](https://peptidevox.com/#r9) As an unapproved research chemical, Bronchogen plausibly falls under S0, so any WADA-tested athlete or military service member should treat it as prohibited and consult their anti-doping authority.

**Bottom line.** Bronchogen pairs mechanistically interesting biology with a near-total absence of human proof. The honest evidence ceiling is Grade C: it reversed bronchial remodeling in a rat NO₂-COPD model and altered differentiation-gene expression while binding DNA in human cell cultures, but what is proven in humans is nothing — no RCTs, no cohorts, no registered trials, and the entire base traces to one Russian research group whose direct peptide-to-DNA mechanism remains independently unreplicated. Add a sequence-reporting inconsistency (ADEL vs AEDL), an unapproved research-chemical legal status, a likely WADA S0 prohibition, and the sterility and identity risks of gray-market injectables, and the responsible read is: promising preclinical biology, zero human efficacy or safety validation.

---
Source: https://peptidevox.com/peptide-encyclopedia/bronchogen
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt